Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia

BJU International

Volumn 97, Issue 6, 2006, Pages 1262-1266

  Nitti, Victor W ^a   Dmochowski, Roger ^b   Appell, Rodney A ^c   Wang, Joseph T ^d   Bavendam, Tamara ^d   Guan, Zhonghong ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

Continence; Nocturia; Overactive bladder; Tolterodine

Indexed keywords

PLACEBO; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THORAX PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CONSTIPATION; CRESOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS; XEROSTOMIA;

EID: 33745197986     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06146.x     Document Type: Article

References (31)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61: 37 49
2. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002 60 ( Suppl. 5 7 12
3. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 57: 414 21
4. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002 24: 616 28
5. Freeman R, Hill S, Millard R, Slack M, Sutherst J Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003 102: 605 11
6. Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 2004 27: 1043 57
7. Anderson RU, Mobley D, Blank B, Slazstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999 161: 1809 12
8. Chancellor MB, Freedman S, Mitcheson HD, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000 19: 83 91
9. Davila GW, Daugherty CA, Sanders SW Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166: 140 5
10. Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 2001 98: 97 102
11. Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 168: 580 6
12. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003 78: 687 95
13. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003 20: 392 9
14. Barkin J, Corcos J, Radomski S et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004 26: 1026 36
15. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 172: 1919 24
16. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004 93: 303 10
17. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004 45: 420 9
18. Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004 171: 2311 5
19. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87: 760 6
20. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20: 327 36
21. Rackley R, Weiss JP, Rovner ES et al. Night-time dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006 in press
22. European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products. Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence. Report no. CPMP/EWP/18/01, London: December 2002
23. Diokno A, Lee P, Zorn BH et al. Factors associated with clinical assessment of overactive bladder and selection of treatment. Clin Ther 2001 23: 1542 51
24. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001 57: 1044 50
25. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003 92: 948 54
26. Coyne K, Payne C, Bhattacharyya S et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004 7: 455 63
27. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002 18: 177 84
28. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002 41: 588 95
29. Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002 41: 6 14
30. van Brummen HJ, Heintz AP, van der Vaart CH. The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. Neurourol Urodyn 2004 23: 38 42
31. Brown JS, McNaughton KS, Wyman JF et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003 61: 802 9